2型糖尿病新药及候选药物临床试验研究进展  

Research progress in clinical trials of new drugs and candidate drugs for type 2 diabetes mellitus

作　　者：周鑫 王智 杜文雨[1,2] 刘子涵 李颖 董占军[2] ZHOU Xin;WANG Zhi;DU Wenyu;LIU Zihan;LI Ying;DONG Zhanjun(Graduate School of Hebei Medical University,Shijiazhuang 050017,Hebei,China;Hebei General Hospital,Shijiazhuang 050057,Hebei,China)

机构地区：[1]河北医科大学研究生学院,河北石家庄050017 [2]河北省人民医院药学部,河北石家庄050057

出　　处：《中国临床药理学与治疗学》2024年第10期1185-1193,共9页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：河北省医学科学研究课题(20210037)。

摘　　要：目前进入临床研究阶段的2型糖尿病(T2DM)治疗药物主要有钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂如荣格列净等,SGLT1/2抑制剂如LIK066等,二肽基肽酶4(DPP-4)抑制剂如DBPR108等,胰高血糖素样肽1(GLP-1)受体激动剂如艾本那肽等,G蛋白偶联受体40(GRP40)激动剂如SCO-267等和葡萄糖激酶(GK)激动剂如PB201等。本文简要概述T2DM治疗领域靶向上述靶点相关药物的临床研究进展,以期为T2DM患者的治疗提供参考。A number of drugs for the treatment of type 2 diabetes mellitus(T2DM)are currently under clinical investigation,including the sodiumdependent glucose transporters 2(SGLT2)inhibitor rongliflozin,the SGLT1/2 inhibitor LIK066,the dipeptidyl peptidase-4(DPP-4)inhibitor DBPR108,the glucagon-likepeptide-1 receptor(GLP-1R)agonist CJC-1134-PC,the G-protein-coupled receptor 40(GRP40)agonist SCO-267 and the Glucokinase(GK)agonist PB201.This article briefly reviews the clinical research progress of drugs targeting the above targets in the field of T2DM treatment,in order to provide reference for the treatment of T2DM patients.

关 键 词：2型糖尿病 临床试验 药物靶点 

分 类 号：R965.2[医药卫生—药理学]